WebIronwood Pharmaceuticals Ironwood is dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of GI patients. Industry Biotechnology … WebIronwood Pharmaceuticals, Inc. is an entrepreneurial pharmaceutical company. Ironwood Pharmaceuticals Company Stats. ... Logo Licensing Reprints/Plaques Spreadsheets Forbes Profile
IRWD Ironwood Pharmaceuticals Inc. Cl A Profile MarketWatch
WebFeb 17, 2024 · Ironwood Pharmaceuticals Inc. reported fourth quarter revenue and adjusted earnings above analyst expectations. Fourth quarter total revenue came to $116.7 million, … WebIronwood Pharmaceuticals is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI … Mr. Emany has served as our chief financial officer since December 2024. Prior to … The Boston Globe named Ironwood Pharmaceuticals a Top Place to Work for … Our in-market product, LINZESS® (linaclotide), discovered in-house, is the … Ironwood Pharmaceuticals wants to make our careers website accessible to all … In November 2024 into a collaboration and license option agreement with COUR … Ironwood Pharmaceuticals. 100 Summer Street Suite 2300 Boston MA 02110. … Ironwood Pharmaceuticals is a patient-focused, biopharmaceutical company on … By providing your email address below, you are providing consent to Ironwood … One in five Americans suffer from GI diseases, resulting in millions of hospital … darius mcghee highlights
Working at Ironwood Pharmaceuticals Glassdoor
WebWebsite: www.ironwoodpharma.com Headquarters: Cambridge, MA Size: 201 to 500 Employees Type: Company - Public (IRWD) Industry: Biotech & Pharmaceuticals Revenue: … WebFeb 17, 2024 · Ironwood Pharmaceuticals Inc. reported fourth quarter revenue and adjusted earnings above analyst expectations. Fourth quarter total revenue came to $116.7 million, down from $126.3 million a... WebApr 1, 2024 · – Ironwood capitalizing on GI leadership and expertise in an effort to bring innovative therapies to patients – – Strategy centered on accelerating LINZESS ® (linaclotide) growth and advancing late-stage programs IW-3718 and MD-7246 – – Business poised to drive revenue growth and begin generating profits – Ironwood Pharmaceuticals, … darius miles accused of murder